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tp://dx.doi.org/10.1016/j.jfma.201
29-6646/Copyright ª 2014, ElsevierOf approximately 25,000 genes in the entire human
genome, the mitochondrial genome (mtDNA) accounts for a
very small fraction of it and encodes only 37 genes.
Currently, preimplantation genetic diagnosis (PGD) has
emerged as a powerful tool to prenatally diagnose inherited
genetic diseases, especially nuclear genetic diseases;
however, it is not that useful for diagnosing inherited
mitochondrial diseases. Recently, the US Food and Drug
Administration advisory panel conducted a hearing to
evaluate the feasibility of a novel in vitro fertilization (IVF)
technique that might provide hope for women with mito-
chondrial diseases to allow them to have healthy children.
This novel technique was approved in the United Kingdomrs declare no conflicts of
f Virginia Health System, Di-
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Taiwan LLC & Formosan Medicalin June 2013. The embryo generated using this technique is
termed a “three-parent embryo” since its genome is
derived from three sources.
The mitochondrion is a crucial eukaryotic organelle
that regulates cell energy production through oxidative
phosphorylation. Because of its role in energy meta-
bolism, mitochondria are abundant in tissues with high
energy demands, such as brain, heart, muscle, liver, kid-
ney, and central nervous system tissues. This unique
feature characterizes multiorgan involvement in mito-
chondrial genetic diseases. It has been estimated that the
lifetime risk of developing a mitochondrial disease is
approximately 1 in 5000 live births.1 According to the
Health Promotion Administration, Ministry of Health and
Welfare, Taiwan, approximately 50 inherited mitochon-
drial diseases and up to 400 affected families in Taiwan
were reported, which corresponds to an approximate
mutation rate of 1/10,000 (http://gene.hpa.gov.tw/
index.php?moZDiseasePaper&acZpaper1_show&cateZ
Set1&csnZ71&snZ144).Association. All rights reserved.
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mutations in the mtDNA or in the nuclear genes involved in
mitochondrial function. In humans, the mtDNA is exclu-
sively maternally inherited. Although sperm also carries
mtDNA, its mtDNA is specifically removed by ubiquitina-
tion.2 Moreover, compared with the oocyte which has
almost 100,000 copies of mtDNA, sperm contains only 100
copies. After fertilization, the dilution effect and the
bottleneck phenomenon might preferentially exclude the
transmission of paternal mtDNA and lead to the maternal
inheritance pattern of mtDNA.
Because of mitochondrial heteroplasmy and the bottle-
neck phenomenon,3 it is challenging to utilize PGD for
prenatal diagnosis of inherited mitochondrial diseases.4
Heteroplasmy represents a mixture of mutant and normal
mtDNA in a given cell, tissue, or an individual. A higher
heteroplasmy of the mutant mtDNA predisposes to a
greater chance of developing a mitochondrial disease. The
bottleneck phenomenon would cause a marked variation of
mutant mtDNA being transmitted to the embryo from a
heteroplasmic mother. Thus, a woman carrying a low level
of heteroplasmic mutant mtDNA may still transmit a sub-
stantial amount of mutant mtDNA to her offspring. There is
also a concern about whether the biopsied blastomeres or
the trophectoderm is able to precisely represent the entire
embryo.5 Hence, it is difficult to accurately predict the risk
of transmission of a mitochondrial disease, particularly with
regard to PGD, which has no useful role to play in diag-
nosing inherited mitochondrial diseases when a woman
carries homoplasmic mutant mtDNA. These concerns plus
recent advances in three-parent IVF have prompted the US
Food and Drug Administration to step forward to evaluate
the therapeutic potential of this technique.
In the three-parent embryo, the nuclear genome origi-
nates from both male and female biological parents just
like every other embryo fertilized in the natural way,
however, its mtDNA is derived from an oocyte of a healthy
woman. Thus, it is hoped that the three-parent embryo will
prevent the transmission of mutant mtDNA from the
affected woman to the embryo. Currently, two major pro-
cedures are utilized to generate three-parent embryos: the
pronuclear transfer and the spindle transfer. The pronu-
clear transfer is performed by removing both normal pro-
nuclei from a zygote carrying mutant mtDNA to a donated
enucleated zygote.6 Alternatively, the spindle transfer is
achieved by transferring the nuclear genome from an un-
fertilized oocyte of the affected woman to a mtDNA
mutation-free oocyte from which the nuclear geneticmaterial has been removed.7 Because of the preferential
elimination and dilution effect of paternal mtDNA after
fertilization, paternal mtDNA is less likely to be used in
place of the mtDNA from the donor woman.
Three-parent IVF provides a plausible therapeutic future
for women with mitochondrial diseases, however, this
technique also carries risks and ethical concerns. Both
procedures of three-parent IVF still harbor the risk of car-
rying over a variable fraction of mutant mtDNA to the
embryos,7,8 that might potentially cause a detrimental ef-
fect in the fertilized embryo because of heteroplasmy and
the bottleneck phenomenon. The possibility of generating
abnormally fertilized embryos is also observed.7,8 More-
over, the development of a three-parent embryo might also
pose a challenge to the definition of biological parentage
because of its three origins of genetic material. Lastly,
subsequent emerging legal issues, profit-oriented behav-
iors, and the social impacts related to three-parent em-
bryos might be different from gestational surrogacy issues
we are now facing and should be well-assessed in advance.References
1. Haas RH, Parikh S, Falk MJ, Saneto RP, Wolf NI, Darin N, et al.
Mitochondrial disease: a practical approach for primary care
physicians. Pediatrics 2007;120:1326e33.
2. Sutovsky P. Ubiquitin-dependent proteolysis in mammalian
spermatogenesis, fertilization, and sperm quality control:
killing three birds with one stone. Microsc Res Tech 2003;61:
88e102.
3. Taylor RW, Turnbull DM. Mitochondrial DNA mutations in human
disease. Nat Rev Genet 2005;6:389e402.
4. Sallevelt SC, Dreesen JC, Drusedau M, Spierts S, Coonen E, van
Tienen FH, et al. Preimplantation genetic diagnosis in mito-
chondrial DNA disorders: challenge and success. J Med Genet
2013;50:125e32.
5. Amato P, Tachibana M, Sparman M, Mitalipov S. Three-parent
in vitro fertilization: gene replacement for the prevention of
inherited mitochondrial diseases. Fertil Steril 2014;101:31e5.
6. McGrath J, Solter D. Nuclear transplantation in the mouse
embryo by microsurgery and cell fusion. Science 1983;220:
1300e2.
7. Tachibana M, Sparman M, Sritanaudomchai H, Ma H, Clepper L,
Woodward J, et al. Mitochondrial gene replacement in primate
offspring and embryonic stem cells. Nature 2009;461:367e72.
8. Craven L, Tuppen HA, Greggains GD, Harbottle SJ, Murphy JL,
Cree LM, et al. Pronuclear transfer in human embryos to pre-
vent transmission of mitochondrial DNA disease. Nature 2010;
465:82e5.
